Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GRK6 | P43250 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379657 | 0.83 | ADORA1 (0.41) | — | |
| SCHEMBL30852279 | 0.82 | SLC5A2 (0.47) | SLC5A2NPC1RAB9ATSHRCA1 | |
| SCHEMBL30852312 | 0.82 | SLC5A2 (0.47) | SLC5A2NPC1RAB9ATSHRCA1 | |
| SCHEMBL30852351 | 0.82 | SLC5A2 (0.47) | SLC5A2NPC1RAB9ATSHRCA1 | |
| SCHEMBL14742691 | 0.81 | FBP1 (0.48) | — | |
| SCHEMBL29508765 | 0.81 | FBP1 (0.48) | — | |
| SCHEMBL769912 | 0.81 | FBP1 (0.48) | — | |
| Pyrophosphoric Acid SCHEMBL14742591 | 0.79 | FBP1 (0.45) | — | |
| SCHEMBL10788242 | 0.77 | SLC5A1 (0.44) | SLC5A2 | |
| SCHEMBL10773805 | 0.77 | SLC5A1 (0.44) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239897-A1 | PROMOTERS FROM CORYNEBACTERIUM GLUTAMICUM AND USES THEREOF IN REGULATING ANCILLARY GENE EXPRESSION | ZYMERGEN INC. | 2020-07-30 | — | — | US | disclosed |
| US-7723076-B2 | Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy | THE BURNHAM INSTITUTE (US) | 2010-05-25 | — | — | US | disclosed |
| US-20060275876-A1 | Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy | PELLECCHIA MAURIZIO | 2006-12-07 | — | — | US | disclosed |
| US-20040132102-A1 | Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy | BURNHAM INSTITUTE, THE | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060275876-A1 | Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy | MRPS27, MRPS34, MRPS22 | SLC5A2 4746/4885NPC1 3264/4885RAB9A 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.